Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02039778 : Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma
PhasePhase 1/Phase 2
AgesMin: 18 Years Max: 70 Years
Inclusion Criteria:

- Patients with newly diagnosed with high grade glioma (grade 3 or 4) having completed

- Patients must be ? 18 and ? 70 years of age;

- WHO/ECOG Performance Status of 2 or less.

- MRI of the brain as delineated above.

- Patients must sign a study-specific informed consent prior to study entry.

Exclusion Criteria:

- Evidence of brainstem involvement on radiographs;

- Evidence of oligodendroglioma histology.

- Evidence of progressive disease at the time of study entry;

- Evidence of extracranial distant metastatic disease;

- Prior cranial irradiation;

- Patients may not be entered on other studies that have progression free, disease
free, or overall survival as a primary endpoint;

- Patients with synchronous or prior malignancy, other than non-melanomatous skin
cancer unless disease free greater than 3 years;

- Pregnant women are ineligible as treatment involves unforeseeable risks to the
participant and to the embryo or fetus; patients with childbearing potential must
practice appropriate contraception.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557